Immunome Inc. (IMNM) Institutional Ownership

Ownership Summary

Immunome Inc. (NASDAQ:IMNM) appears in 198 institutional 13F filings for the quarter ending March 2026.

• These investors collectively held 103.8% of Immunome's outstanding shares in March 2026, down from 133.4% in December 2025.
• They increased total shares held in Immunome by 18.46% from the prior quarter, while the number of investors in IMNM increased 37.5% year over year.
• Of these 198 holders, 125 added to their stakes in Immunome, 45 trimmed positions, and 28 made no changes.
• In total, institutional investors held 117.46Mn shares in Immunome as of March 2026, up by 18.31Mn shares quarter on quarter, and up 34.64Mn shares year over year.
• As of March 31, 2026, FMR LLC held the largest stake in Immunome with 16.97Mn shares, accounting for 15.0% of total shares outstanding.
• The biggest buyers of Immunome for the quarter ending March 2026 included VANGUARD CAPITAL MANAGEMENT LLC (4.43Mn), WELLINGTON MANAGEMENT GROUP LLP (3.8Mn), PRICE T ROWE ASSOCIATES INC /MD/ (2.86Mn), T. Rowe Price Investment Management, Inc. (1.73Mn), State Street Corp (1.53Mn).
• Top sellers of IMNM stock for the quarter ending March 2026 included CITADEL ADVISORS LLC (1.66Mn), BALYASNY ASSET MANAGEMENT L.P. (1.18Mn), Enavate Sciences GP, LLC (1.15Mn), Jefferies Financial Group Inc. (839.28K), ExodusPoint Capital Management, LP (664.21K).
• Per Business Quant, the top 10 investors in IMNM for the quarter ending March 2026 include FMR LLC (16.97Mn), T. Rowe Price Investment Management, Inc. (16.36Mn), BlackRock, Inc. (8.17Mn), Redmile Group, LLC (5.56Mn), State Street Corp (5.4Mn), PRIMECAP MANAGEMENT CO/CA/ (4.79Mn), WELLINGTON MANAGEMENT GROUP LLP (4.73Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.43Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (4.1Mn), Enavate Sciences GP, LLC (3.61Mn).